This seminar in writing introduced novel cancer thermal therapy using functionalized heat-generating nanoparticles with about 100 nm diameter, administered via intratumor injection. The nanoparticles named magnetites cationic lipid composite particles (MCL particles) were composed of about 10 nm magnetites (Fe₃O₄), a cationic lipid and two neutral lipids. Magnetites in MCL particles generated heat due to external alternating magnetic field (AMF) irradiation to kill cancer cells nearby located. A cationic lipid component conferred several functions to MCL particles necessary for its efficacy and safety. Origination of the therapy with MCL particles was summarized by referring to our earlier reports in 1996-2014. Further characterizations of MCP particles and utility of heat dose index for treatment control were summarized by referring to our recent reports in 2019-2022. Unpublished data were supplemented to support overall understanding of the therapy. Purpose of this seminar is to clarify novel principle of the therapy in comparison with conventional thermal therapies and to discuss its clinical application.

The last three decades have witnessed in Europe an increasing interest from institutions, and creative communities in independent research connected to crafting, DIY, maker culture, and design activism. A new generation of designers has focused on the experimentation of processes, materials, and technologies used as a vehicle for socio-political and environmental messages and as the starting point of solid narrative projects. This paper aims to analyse this phenomenon inside the niche of Collectible Design, a field in recent years of great interest by galleries and institutions for its ability to embrace material and technological research as well as craftsmanship and art. We investigate the phenomenon, through a series of interviews with designers such as Shahar Livne, Eugenia Morpurgo, Pleun van Dijk, Tellurico, and Standard 404, selected for their ability to use experimental materials and technologies, as communicative media for reflections on systemic issues.

Meigs’ syndrome is a rare triad of a benign ovarian fibroma (or fibroma‑like tumor), ascites, and pleural effusion that resolves after tumor resection. A 53‑year‑old multiparous woman presented with progressive exertional dyspnea and right‑sided pleuritic chest pain. Respiratory and cardiac evaluations were initially unrevealing. Bedside assessment identified mild right basal dullness, and point‑of‑care abdominal ultrasound demonstrated mild free fluid and a solid right adnexal mass. Chest radiography confirmed a small right pleural effusion. Without computed tomography and without diagnostic paracentesis or thoracentesis, Meigs’ syndrome was suspected. The patient underwent laparotomy with total abdominal hysterectomy and bilateral salpingo‑oophorectomy. Histopathology confirmed an ovarian fibroma. Postoperatively, symptoms resolved dramatically, and follow‑up imaging demonstrated complete resolution of the pleural effusion and ascites. This case highlights the importance of considering gynecologic etiologies in unexplained pleural effusion and dyspnea, especially when accompanied by abdominal distension or pelvic pressure.

Background: Tobacco endgame, defined as elimination of commercial tobacco sales The U.S. tobacco control landscape is a complex, adaptive system shaped by diverse stakeholders, evolving products and regulations, shifting social norms, and the strategic countermeasures of a powerful industry. Managing such complexity requires more than isolated interventions—it demands a coordinated, enterprise-wide approach that accounts for dynamic interactions, feedback loops, and emergent risks. Objective: Drawing on complex systems thinking, Zachman enterprise architecture model, and public health best practices, we conceptualize tobacco control as an evolving enterprise progressing through six interconnected phases: (1) Conception & Initiation, (2) Policy & System Design, (3) Implementation & Operation, (4) Evaluation & Adaptation, (5) Consolidation & Endgame Transition, and (6) Sustainment or Sunset. Each phase incorporates governance structures, performance benchmarks, and transition criteria designed to manage interdependence and reduce systemic vulnerabilities. Results: The lifecycle framing emphasizes how tobacco control in the U.S. can evolve as a complex, adaptive enterprise—integrating public health objectives with legal, operational, and cultural change processes. This model supports strategic sequencing, cross-sector alignment, and risk mitigation against emergent industry tactics, enabling a resilient and measurable pathway to the endgame. Conclusions: Seeing tobacco control as a complex enterprise that operates under a lifecycle model may offer a roadmap for achieving and sustaining the tobacco endgame. Using this approach may enhance policy coherence, resource efficiency, and adaptability, ensuring tobacco endgame is achieved.